Chester County News and Community Website
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced promising results from its recent Phase II/III clinical trial for its lead drug candidate, Buntanetap, targeting Alzheimer’s disease (AD). The …
Annovis Bio’s Alzheimer’s Drug Shows Promise in Phase II/III Trial Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced a positive outcome from the Data and Safety Monitoring Board (DSMB) review of its Phase 1/2 ArMaDa clinical trial for OCU410, a …
Ocugen’s Gene Therapy Shows Promise in Early Trial for Age-Related Macular Degeneration Read More
PHILADELPHIA, PA — Salient medical exploration at The Wistar Institute may have shed light on the role of the Epstein-Barr Virus (EBV) in the development of multiple sclerosis (MS). Paul …
Unlocking Epstein-Barr Virus Secrets: Potential Breakthrough in Battle Against Multiple Sclerosis Read More
MALVERN, PA — YPrime has unveiled a new glucometer functionality that integrates seamlessly with its electronic Clinical Outcome Assessment (eCOA) platform. This innovation, developed alongside diabetes patients, aims to revolutionize …
YPrime Launches Groundbreaking Glucometer Feature for Clinical Trials Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced a significant milestone in its research with the publication of a new article in the journal Biomolecules. The study focuses on …
Annovis Bio Publishes Key Study on Posiphen Drug Across Species Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focusing on innovative therapies, announced the completion of dosing in the second cohort of its groundbreaking GARDian clinical trial for …
Ocugen Advances with Phase 1/2 Trial for Stargardt Disease Treatment Read More
MALVERN, PA — At the recent American Urological Association (AUA) annual meeting held from May 3-6, 2024, Endo, Inc. took the spotlight with the unveiling of new research on Peyronie’s …
Innovations in Peyronie’s Disease Treatment Highlighted at AUA Annual Meeting Read More
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) announced this week new research findings that highlight the benefits of the Prostatic Urethral Lift (PUL) using the UroLift™ System for benign prostatic …
New Research Sheds Light on Superior Patient Experience with UroLift System in Prostate Treatment Read More
WAYNE, PA — XyloCor Therapeutics, Inc. recently revealed the final results from the Phase 2 segment of its EXACT clinical trial at the Society for Cardiovascular Angiography & Interventions (SCAI) …
XyloCor Therapeutics Announces Promising Results for Gene Therapy in Treating Refractory Angina Read More
BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) has unveiled hopeful results from its Maximum Tolerated Dose (MTD) study of Probudur™, a long-acting pain management drug, in Sprague-Dawley rats. Probudur, …
Virpax Pharmaceuticals’ Probudur Shows Promising Results in Pain Management Study Read More